Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | XBP1 | P17861 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5433984 | 0.85 | HDAC3 (0.39) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL3696389 | 0.85 | HDAC3 (0.39) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL24846023 | 0.81 | IDO1 (0.38) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL11009383 | 0.79 | IDO1 (0.37) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL14012905 | 0.79 | IDO1 (0.37) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL11009384 | 0.79 | IDO1 (0.37) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL77082 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL16097771 | 0.78 | HDAC3 (0.38) | ALDH1A1IDO1TP53TSHRL3MBTL1 | |
| SCHEMBL921425 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTXBP1MAPK1RAB9A | |
| SCHEMBL8295700 | 0.76 | IDO1 (0.36) | ALDH1A1MAPTXBP1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1290676-A | — | — | None | — | — | JP | disclosed |
| US-12612390-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4421072-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240116905-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-3781561-B1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
| EP-4031527-A1 | HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| US-11274095-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-4877795-A | 4H-quinolizin-4-one compounds useful for the treatment of allergic bronchial asthma, allergic rhinitis atropic dermatitis and the like | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1989-10-31 | — | — | US | disclosed |
| EP-0309260-A1 | 4H-Quinolizin-4-one compounds exhibiting therapeutic activities | Kissei Pharmaceutical Co., Ltd. (JP) | 1989-03-29 | — | — | EP | disclosed |
| US-4786638-A | TREATMENT OR PREVENTION OF DIABETIC COMPLICATIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0277755-A1 | 4H-quinolizin-4-one compounds exhibiting therapeutic activities | Kissei Pharmaceutical Co. Ltd. (JP) | 1988-08-10 | — | — | EP | disclosed |
| US-4542140-A | ANTIULCER, ANTISECRETORY, GASTROINTESTINAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-09-17 | — | — | US | disclosed |
| US-4221737-A | ANTIULCER | BRISTOL-MYERS COMPANY (US) | 1980-09-09 | — | — | US | disclosed |
| US-4200760-A | ANTIULCER, H2-RECEPTOR BLOCKING AGENTS | BRISTOL-MYERS COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
| US-4154599-A | Alkylthioaminoacrylonitriles and use as herbicides | GULF OIL CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4098598-A | PLANT GROWTH REGULATORS | HOFFMANN-LA ROCHE INC. (US) | 1978-07-04 | — | — | US | disclosed |
| US-4028089-A | BENZOXAZOLINYLIDENE-MALONITRILE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PEBP1, PLTP | ALDH1A1 4749/4885MAPT 2749/4885XBP1 417/4885 |
| US-20240116905-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TPMT, TET1, DNMT1 | ALDH1A1 230/4885MAPT 2604/4885XBP1 3754/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | ALDH1A1 2145/4885MAPT 1039/4885XBP1 2936/4885 |
| US-11274095-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | TPMT, TET1, DNMT1 | ALDH1A1 230/4885MAPT 2604/4885XBP1 3754/4885 |
| US-12612390-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | NSD1, DOT1L, EHMT2 | ALDH1A1 2327/4885MAPT 1517/4885XBP1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.